ANTI-PTK7 ANTIBODY-DRUG CONJUGATES

(19)

(11)

EP 3 137 114 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.08.2021 Bulletin 2021/31

(45)	Mention of the grant of the patent:
	23.12.2020 Bulletin 2020/52

(21)	Application number: 15774735.3

(22)	Date of filing: 27.04.2015

(51)

International Patent Classification (IPC):

A61K 47/50^(2017.01)
C07K 16/30^(2006.01)
A61K 47/68^(2017.01)
A61P 35/02^(2006.01)

C07K 16/26^(2006.01)
C07K 16/40^(2006.01)
A61P 35/00^(2006.01)

(86)	International application number:
	PCT/US2015/027791

(87)	International publication number:
	WO 2015/168019 (05.11.2015 Gazette 2015/44)

(54)	ANTI-PTK7 ANTIBODY-DRUG CONJUGATES ANTI-PTK7-ANTIKÖRPER-ARZNEIMITTELKONJUGATE CONJUGUÉS MÉDICAMENT-ANTICORPS ANTI-PTK7

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

30.04.2014 US 201461986520 P

(43)	Date of publication of application:
	08.03.2017 Bulletin 2017/10

(60)	Divisional application:
	20159103.9 / 3711780

(73)	Proprietors:
	Pfizer Inc. New York, NY 10017 (US) AbbVie Stemcentrx LLC North Chicago, IL 60064 (US)

(72)	Inventors:
	DAMELIN, Marc Isaac Needham Heights MA 02494-1506 (US) SAPRA, Puja River Edge, New Jersey 07661 (US) BANKOVICH, Alexander John San Francisco, California 94017 (US) DYLLA, Scott J. Menlo Park CA 94026 (US)

(74)	Representative: Wilding, James Roger et al
	Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG London SE1 9SG (GB)

(56)

References cited: :

WO-A1-2012/112943
WO-A2-2007/067730
US-A1- 2013 129 753

WO-A1-2012/162482
US-A1- 2013 122 020

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).